View in EDS

First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin.

Saved in:
Bibliographic Details
Title: First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin.
Authors: Iacovelli, R.1 (AUTHOR) Roberto.iacovelli@policlinicogemelli.it, Ciccarese, C.1 (AUTHOR), Brunelli, M.2 (AUTHOR), Battelli, N.3 (AUTHOR), Buttigliero, C.4 (AUTHOR), Caserta, C.5 (AUTHOR), Buti, S.6,7 (AUTHOR), Santini, D.8,9 (AUTHOR), Carella, C.10 (AUTHOR), Galli, L.11 (AUTHOR), Verri, E.12 (AUTHOR), Ermacora, P.13 (AUTHOR), Merler, S.14 (AUTHOR), Masini, C.15 (AUTHOR), De Vivo, R.16 (AUTHOR), Milesi, L.17 (AUTHOR), Spina, F.18 (AUTHOR), Rizzo, M.19 (AUTHOR), Sperduti, I.20 (AUTHOR), Fornarini, G.1,21 (AUTHOR)
Source: Annals of Oncology. Nov2022, Vol. 33 Issue 11, p1179-1185. 7p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2022.07.011